Market Need BrightInsight addresses the patient persistence gap in biopharma, offering a platform that unifies hubs and CRMs to detect drop-off signals and trigger timely interventions. This presents a strong upsell opportunity for pharma and biotech clients seeking to improve adherence, reduce unrealized value, and protect existing therapy launches.

Expansion Momentum Recent high-profile partnerships and funding rounds signal growth and credibility. Strategic ties with Havas Health and new investment from major firms indicate a broader market push, creating opening to propose integrated digital persistence solutions to larger brands and networks.

Technical Fit The solution is designed to layer over existing hubs and CRMs without rip-and-replace, leveraging a QMS-validated compliance framework. This makes it an attractive, lower-friction deployment for regulated biopharma environments seeking scalable, compliant digital health integrations.

Therapy-agnostic Value Being therapy-agnostic and globally scalable widens addressable markets across multiple therapeutic areas and regions, enabling cross-sell opportunities to brands with diverse biologic therapies and international commercial needs.

Evidence-Based ROI Real-world results show a 4% lift in adherence and persistence in a Sanofi study, translating to meaningful revenue recovery over multiple years. This ROI narrative can be leveraged to engage senior decision-makers focused on patient outcomes and value realization.